Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

159
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
159
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

155
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
155
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

3.9K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
3.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.9K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient sensitization profile and fish species' tolerance in children with IgE-mediated fish allergy.

Allergologia et immunopathologia·2026
Same author

Panallergen sensitization in children with eosinophilic esophagitis: a pilot study.

Frontiers in allergy·2026
Same author

Screening practices for diabetic peripheral neuropathy in pediatric type 1 diabetes: a nationwide survey by the ISPED Diabetes Study Group.

Acta diabetologica·2026
Same author

Reduced Diabetes Burden Over Glycemic Gains With the Dexcom G7 Upgrade in Youth on Automated Insulin Delivery System.

Diabetes, obesity & metabolism·2026
Same author

Efficacy and safety of non-pharmacological interventions for gastroesophageal reflux and gastroesophageal reflux disease in children: a systematic review.

Italian journal of pediatrics·2026
Same author

Effectiveness and safety of the MiniMed™ 780G in newly diagnosed adolescents with type 1 diabetes: an observational real-world study.

Endocrine·2026

Related Experiment Video

Updated: May 5, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.7K

Pidotimod: the past and the present.

Gian Vincenzo Zuccotti1, Chiara Mameli

  • 1Department of Pediatrics, Luigi Sacco Hospital, University of Milan, Via GB Grassi 74, 20157, Milan, Italy. gianvincenzo.zuccotti@unimi.it.

Italian Journal of Pediatrics
|December 10, 2013
PubMed
Summary

Acute respiratory tract infections (ARTIs) remain a significant global health challenge, particularly in children. Pidotimod, an immunostimulant, shows promise, but further research is needed to confirm its efficacy in preventing ARTIs.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

56.9K

Related Experiment Videos

Last Updated: May 5, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

56.9K

Area of Science:

  • Pediatric Immunology
  • Infectious Diseases
  • Pharmacology

Background:

  • Acute respiratory tract infections (ARTIs) persist as a major global health concern, especially in pediatric populations, despite advances in antibiotics and vaccines.
  • Viral ARTIs in children remain a significant challenge, highlighting the need for novel preventative and therapeutic strategies.
  • Immunostimulants offer a potential approach to enhance innate defense mechanisms against ARTIs in children.

Discussion:

  • Pidotimod is an immunostimulant under investigation for its potential role in preventing ARTIs in children.
  • Recent research aims to elucidate the in vitro and in vivo mechanisms of action of Pidotimod.
  • Evaluating Pidotimod requires improved research methodologies and a deeper understanding of clinical immunology.

Key Insights:

  • While Pidotimod has been introduced in some countries, its precise mechanisms of action require further clarification.
  • Preclinical studies are crucial for understanding how Pidotimod interacts with the immune system.
  • Robust clinical evidence, particularly from randomized controlled trials, is essential to establish Pidotimod's efficacy.

Outlook:

  • Future research should focus on rigorous preclinical investigations to fully understand Pidotimod's immunomodulatory effects.
  • Well-designed in vivo studies, especially randomized controlled trials, are critical for validating Pidotimod's effectiveness in preventing pediatric ARTIs.
  • Continued advancements in clinical immunology research will guide the evaluation of Pidotimod and similar compounds.